Photo of a woman working
Photo of a woman working

Help appropriate patients simplify dosing by choosing the only Sertraline HCl Capsules in 150 mg or 200 mg dosages.*1

For Major Depressive Disorder and Obsessive Compulsive Disorder1

  • Do not initiate treatment with Sertraline HCl Capsules. Use another Sertraline HCl product for initial dose titration and dosages below 150 mg once daily.1

One capsule, two important benefits

150 mg and 200 mg capsules (not actual size)

Reduce pill burden

Achieve 150 mg or 200 mg dosage with ONE capsule1

Support adherence

A single capsule vs multiple pills has the potential to increase patient adherence to treatment2

A real-world retrospective analysis showed that patients taking one pill a day (vs multiple pills) improved adherence.2

Stabilized patients on a lower pill burden had statistically higher adherence and were more likely to remain persistent throughout the 1-year post-index period vs patients on a higher pill burden but the same overall dose.2

Probability of remaining persistent on sertraline


Kaplan-Meier survival curves for probability of remaining persistent with sertraline during the 1-year post-index period for patients who achieved stable dose on different pill regimens. This chart shows Cohort 2 (1 x 100 mg) vs Cohort 3 (2 x 50 mg).2

To view the complete retrospective study, including this graph and a table of the number of people in each cohort, see Wang G, et al. Int J Clin Pract. 2021.

NOTE: The sertraline tablets referred to in this study were not Almatica products.


Patients pay as little as $10 per month for 150 mg or 200 mg Sertraline HCl Capsules, if eligible1

Applies only to commercially insured patients. Benefits are available for cash-paying and not covered patients.


  1. Sertraline HCP Capsules. Prescribing information. Almatica Pharma LLC; 2023.
  2. Wang G, Si T, Imperato JS, et al. Impact of sertraline daily treatment regimen on adherence, persistence and healthcare resource utilisation in patients with major depressive disorder or obsessive-compulsive disorder: a real-world evidence analysis from the United States. Int J Clin Pract. 2021;75(10)e14522.